• Treatment of progressive rheumatoid arthritis resistant to conventional therapy.

Contraindicated in:

• Hypersensitivity
• Previous gold toxicity (e.g. anaphylaxis, necrotizing enterocolitis, pulmonary fibrosis, exfoliative dermatitis, bone marrow aplasia, hematologic disorders)
• OB: Potential for congenital anomalies
• Lactation: Appears in breast milk. Use formula or discontinue auranofin.

Use Cautiously in:

• History of blood dyscrasias
• Rashes
• Severe hepatic or renal dysfunction
• Inflammatory bowel disease
• Patients taking other immunosuppressant drugs
• Pedi: Efficacy and safety not established.

CNS: peripheral neuropathy.

EENT: conjunctivitis, corneal gold deposition.

GU: proteinuria,, hematuria.

Resp: bronchitis, pulmonary fibrosis, pneumonitis.

CV: bradycardia.

GI: GI BLEEDING, abdominal pain, cramping, diarrhea, gingivitis, glossitis, metallic taste, stomatitis, anorexia, difficulty swallowing, ↑ liver enzymes, dyspepsia, flatulence, nausea, vomiting.

Derm: dermatitis, rash, alopecia, urticaria, photosensitivity reactions, pruritus.

Hemat: AGRANULOCYTOSIS, APLASTIC ANEMIA, thrombocytopenia, anemia, eosinophilia, leukopenia.

Misc: ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, ANGIOEDEMA.

Drug-Drug:

• Bone marrow toxicity may be additive with other myelosuppressive agents (antineoplastics, radiation therapy, azathioprine) or high doses of corticosteroids.
• Concurrent use with penicillamine↑ the risk of adverse hematologic or renal reactions.
• May ↑ blood levels of phenytoin.

• Capsules: 3 mg;

• PO (Adults): 6 mg/day in 1–2 doses; may ↑ to 9 mg/day in 3 divided doses if no improvement after 6 mo.

Ridaura

• Inhibits inflammatory process.
• Modifies immune response (immunomodulating properties).

• Relief of pain and inflammation.
• Slowing of the disease process in rheumatoid arthritis.

Therapeutic Classification: antirheumatics (DMARDs), gold compounds

Absorption: 20–25% absorbed from the GI tract.

Distribution: Widely distributed; appears to concentrate in arthritic joints more than in uninvolved joints. Enters breast milk.

Metabolism/Excretion: 60% of absorbed dose slowly excreted by the kidneys; 40% of absorbed dose excreted in the feces.

Half-life: 26 days in blood, 40–128 days in tissue.

(anti-inflammatory activity)

• Instruct patient to take medication exactly as directed; do not skip or double doses. Take missed dose as soon as possible except if next dose is almost due.
• Concurrent therapy with salicylates or other NSAIDs or corticosteroids is usually necessary, especially during the first few mo of gold therapy. Patients should continue physical therapy and ensure adequate rest. Explain that joint damage will not be reversed; the goal is to slow or stop the disease process.
• Emphasize the importance of good oral hygiene to reduce stomatitis.
• Caution patient to use sunscreen and protective clothing to prevent photosensitivity reactions.
• Instruct patient to report symptoms of leukopenia (fever, sore throat, signs of infection); thrombocytopenia (bleeding gums; bruising; petechiae; blood in stools, urine, or emesis); or gold toxicity immediately. Diarrhea may be resolved by decreasing the dose.
• Emphasize the importance of regular visits to health care professional to monitor progress and evaluate blood and urine tests for side effects.
• Discuss the need for contraception while receiving this medication. Advise female patients to notify health care professional promptly if pregnancy is suspected.

au-RANE-oh-fin

NDC Code^*

• 54766- Sebela Pharmaceuticals Inc.
  • 54766-093- RIDAURA
    • 54766-093-06- 60 CAPSULE in 1 BOTTLE (54766-093-06)